Bacthera, the joint venture between Chr. Hansen and Lonza, is to team up with Seres Therapeutics to manufacture Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).
Bacthera, the joint venture between Chr. Hansen and Lonza looking into Live Biotherapeutic Products (LBP), announces Lukas Schüpbach as the company’s new CEO.